What's new in preventing and treating osteoporosis?

被引：6

作者：

Andrews, WC ^{[1
]}

机构：

[1] Med Coll Hampton Rd, Eastern Virginia Med Sch, Dept Obstet & Gynecol, Norfolk, VA 23507 USA

来源：

POSTGRADUATE MEDICINE | 1998年 / 104卷 / 04期

关键词：

D O I：

10.3810/pgm.1998.10.445

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bone mineral density reaches its peak between the ages of 30 and 35 in women. Thereafter, without intervention, bone loss continues gradually, with a significant acceleration in the first 5 to 6 years after menopause. For decades, estrogen replacement has been the mainstay in preventing bone loss and treating osteoporosis after menopause, and it remains first line therapy. However, not all women are able or willing to use estrogen, so effective alternatives have been developed. In this article, Dr Williams summarizes findings of recent research concerning optimal use of estrogen as well as alendronate, etidronate, raloxifene, calcitonin-salmon, and other measures to manage osteoporosis.

引用

页码：89 / +

页数：7

共 31 条

[1]

ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789

[2] THE TRANSITIONAL YEARS AND BEYOND [J].

ANDREWS, WC .

OBSTETRICS AND GYNECOLOGY, 1995, 85 (01) :1-5

[3] COFFEE-ASSOCIATED OSTEOPOROSIS OFFSET BY DAILY MILK CONSUMPTION - THE RANCHO-BERNARDO STUDY [J].

BARRETTCONNOR, E ;

CHANG, JC ;

EDELSTEIN, SL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (04) :280-283

[4]

CHRISTIANSEN C, 1981, LANCET, V1, P459

[5] Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys [J].

Clarkson, TB ;

Anthony, MS ;

Jerome, CP .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :721-726

[6] THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN [J].

COLDITZ, GA ;

HANKINSON, SE ;

HUNTER, DJ ;

WILLETT, WC ;

MANSON, JE ;

STAMPFER, MJ ;

HENNEKENS, C ;

ROSNER, B ;

SPEIZER, FE .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (24) :1589-1593

[7] Risk of venous thromboembolism in users of hormone replacement therapy [J].

Daly, E ;

Vessey, MP ;

Hawkins, MN ;

Carson, JL ;

Gough, P ;

Marsh, S .

LANCET, 1996, 348 (9033) :977-980

[8] Bone-sparing properties of oral contraceptives [J].

DeCherney, A .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (01) :15-20

[9] Esophagitis associated with the use of alendronate [J].

deGroen, PC ;

Lubbe, DF ;

Hirsch, LJ ;

Daifotis, A ;

Stephenson, W ;

Freedholm, D ;

PryorTillotson, S ;

Seleznick, MJ ;

Pinkas, H ;

Wang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1016-1021

[10] Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [J].

Delmas, PD ;

Bjarnason, NH ;

Mitlak, BH ;

Ravoux, AC ;

Shah, AS ;

Huster, WJ ;

Draper, M ;

Christiansen, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) :1641-1647

← 1 2 3 4 →